To do one and to get more: Part I. Diabetes and bone. Issue 10 (6th September 2022)

• Record Type: Journal Article
• Authors: Lee, Wen-Ling; Wang, Peng-Hui; Yang, Szu-Ting; Liu, Chia-Hao; Chang, Wen-Hsun; Lee, Fa-Kung
• Is Part Of: Journal of the Chinese Medical Association. Volume 85:Issue 10(2022)
• Page Start: 965
• Page End: 971
• Publication Date: 2022-09-06
• Subjects: Antidiabetic agents -- Bone health -- Diabetes mellitus (DM) -- Extra-glycemic effects; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000803
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Type 2 diabetes mellitus (T2DM), is a chronic metabolic disease, characterized by the presence of hyperglycemia and insulin resistance. The key treatment strategies for T2DM include modification of lifestyle, medications, and continuous glucose monitoring. DM patients often have DM-associated morbidities and comorbidities; however, disorders of musculoskeletal system are often neglected, compared to other major systems in DM patients. Based on sharing similar pathophysiology of DM and osteoporosis, it is supposed that the use of antidiabetic agents (ADAs) may not only provide the lowering glucose level effect and the maintenance of the sugar homeostasis to directly delay the tissue damage secondary to hyperglycemia but also offer the benefits, such as the prevention of developing osteoporosis and fractures. Based on the current review, evidence shows the positive correlation between DM and osteoporosis or fracture, but the effectiveness of using ADA in the prevention of osteoporosis and subsequent reduction of fracture seems to be inconclusive. Although the benefits of ADA on bone health are uncertain, the potential value of "To do one and to get more" therapeutic strategy should be always persuaded. At least, one of the key treatment strategies as an establishment of healthy lifestyle may work, because it improves the status of insulin resistance and subsequently helps DM control, prevents the DM-related micro- and macrovascular injury, and possibly strengthens the general performance of musculoskeletal system. With stronger musculoskeletal system support, the risk of "fall" may be decreased, because it is associated with fracture. Although the ADA available in the market does not satisfy the policy of "To do one and to get more" yet, we are looking forward to seeing the continuously advanced technology of drug development on diabetic control, and hope to see their extra-sugar–lowering effects.